Screening antivirals with a mCherry-expressing recombinant bovine respiratory syncytial virus: a proof of concept using cyclopamine.
Jenna FixDelphyne DescampsMarie GallouxCécile FerretEdwige BouguyonSiamak ZohariKatarina NäslundSara HägglundRalf AltmeyerJean-François ValarcherSabine RiffaultJean-François EleouetPublished in: Veterinary research (2023)
Bovine respiratory syncytial virus (BRSV) is a pathogenic pneumovirus and a major cause of acute respiratory infections in calves. Although different vaccines are available against BRSV, their efficiency remains limited, and no efficient and large-scale treatment exists. Here, we developed a new reverse genetics system for BRSV expressing the red fluorescent protein mCherry, based on a field strain isolated from a sick calf in Sweden. Although this recombinant fluorescent virus replicated slightly less efficiently compared to the wild type virus, both viruses were shown to be sensitive to the natural steroidal alkaloid cyclopamine, which was previously shown to inhibit human RSV replication. Our data thus point to the potential of this recombinant fluorescent BRSV as a powerful tool in preclinical drug discovery to enable high throughput compound screening.
Keyphrases
- respiratory syncytial virus
- wild type
- drug discovery
- quantum dots
- living cells
- high throughput
- label free
- endothelial cells
- cell free
- liver failure
- fluorescent probe
- electronic health record
- respiratory failure
- amino acid
- intensive care unit
- drug induced
- single molecule
- single cell
- machine learning
- cell therapy
- stem cells
- combination therapy
- mesenchymal stem cells
- protein protein
- aortic dissection
- respiratory tract
- genetic diversity
- risk assessment